 |
|
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery
Clin Mol Hepatol. 2024;30(3):375-387. Published online 2024 Mar 26 DOI: https://doi.org/10.3350/cmh.2023.0535
|
|
Citations to this article as recorded by
 Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis
Jing Chen, Dong Ji, Jidong Jia, Hui Zhuang, Xinxin Zhang, Fu-Sheng Wang, Wenhong Zhang, Xiaoguang Dou, Tawesak Tanwandee, Shiv Kumar Sarin, Rakhi Maiwall, Manoj Kumar, George Boon-Bee Goh, Hasmik Ghazinyan, Anuchit Chutaputti, Pei-Jer Chen, Hong You, Ming
Hepatology International.2025;[Epub] CrossRef Mise à jour concernant le traitement des hépatites virales
Marie Ongaro, Francesco Negro
Schweizer Gastroenterologie.2025; 6(2): 46. CrossRef Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”
Hae Lim Lee, Jeong Won Jang
Clinical and Molecular Hepatology.2024; 30(4): 692. CrossRef
|